Published in J Immunol on December 15, 2004
Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett (2008) 2.04
Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol (2010) 1.59
Interleukin-27: balancing protective and pathological immunity. Immunity (2012) 1.58
New directions in the basic and translational biology of interleukin-27. Trends Immunol (2011) 1.54
Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther (2007) 1.48
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J Exp Med (2007) 1.47
Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol (2013) 1.34
Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol (2014) 1.17
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology (2010) 1.16
Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J Biol Chem (2010) 1.11
New insights into IL-12-mediated tumor suppression. Cell Death Differ (2014) 1.09
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res (2013) 1.07
IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol (2013) 1.06
IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol (2010) 1.06
Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone. Hum Gene Ther (2013) 0.96
Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One (2013) 0.96
The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology (2009) 0.94
Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res (2009) 0.93
A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol (2010) 0.93
Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab (2007) 0.91
Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population. Immunogenetics (2013) 0.91
Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation (2009) 0.90
The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget (2014) 0.90
IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS One (2013) 0.89
IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget (2015) 0.84
The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy (2015) 0.83
Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer. BMC Cancer (2015) 0.81
Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci (2015) 0.81
Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected].. PLoS One (2013) 0.81
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res (2013) 0.80
WSX1 expression in tumors induces immune tolerance via suppression of effector immune cells. PLoS One (2011) 0.80
The WSX-1 pathway restrains intestinal T-cell immunity. Int Immunol (2011) 0.80
Mathematical modeling of interleukin-27 induction of anti-tumor T cells response. PLoS One (2014) 0.79
Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediators Inflamm (2017) 0.78
IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs. J Interferon Cytokine Res (2016) 0.76
Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth. Oncoimmunology (2015) 0.76
Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27. Front Immunol (2017) 0.76
Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47(phox). Sci Rep (2017) 0.75
Interleukin-27 rs153109 polymorphism and the risk of non-small-cell lung cancer in a Chinese population. Onco Targets Ther (2016) 0.75
IL-27: a new target for GVHD prevention. Blood (2016) 0.75
Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway. J Cancer Sci Ther (2014) 0.75
Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells. Oncotarget (2016) 0.75
IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. Oncotarget (2016) 0.75
Tristetraprolin inhibits macrophage IL-27-induced activation of antitumour cytotoxic T cell responses. Nat Commun (2017) 0.75
High Interleukin 27 Production is Associated with Early Clinical Stage and Localized Disease in Patients with Melanoma. J Med Biochem (2016) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A (2004) 4.84
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
Retracted Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res (2009) 2.00
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol (2007) 1.67
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol (2003) 1.53
Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther (2007) 1.48
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res (2003) 1.46
Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood (2008) 1.43
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol (2009) 1.26
The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med (2003) 1.23
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol (2002) 1.20
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology (2010) 1.16
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A (2009) 1.15
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med (2004) 1.15
Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res (2006) 1.13
Visualization and identification of IL-7 producing cells in reporter mice. PLoS One (2009) 1.11
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res (2011) 1.09
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol (2006) 1.04
A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J Immunother (2005) 1.03
High-throughput gene expression profiling of memory differentiation in primary human T cells. BMC Immunol (2008) 0.99
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.99
The role of ascorbate in the modulation of HIF-1alpha protein and HIF-dependent transcription by chromium(VI) and nickel(II). Free Radic Biol Med (2007) 0.97
New approaches for monitoring CTL activity in clinical trials. Adv Exp Med Biol (2007) 0.92
Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol (2002) 0.92
Interleukin-7 regulates Bim proapoptotic activity in peripheral T-cell survival. Mol Cell Biol (2009) 0.92
HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res (2011) 0.88
Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials. J Immunother (2009) 0.88
Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J Immunother (2006) 0.86
TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells. J Immunol (2010) 0.86
T cell tolerance to tumors and cancer immunotherapy. Adv Exp Med Biol (2007) 0.85
HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127. AIDS (2013) 0.83
Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells. J Biol Chem (2011) 0.83
High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery. Cancer Invest (2012) 0.83
Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line. Cancer Genet Cytogenet (2005) 0.82
Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors. J Immunother (2006) 0.79
New perspectives in cancer immunotherapy and immunomonitoring. Future Oncol (2009) 0.78
Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma. J Natl Cancer Inst (2006) 0.77
Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22-25 April 2013, Krakow, Poland. Cancer Immunol Immunother (2013) 0.76
Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture. PLoS One (2011) 0.75
New paradigms in inflammation: where to next? Immunol Rev (2008) 0.75
Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities. PLoS One (2012) 0.75
From cell regulation to patient survival: 2nd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, Budapest, 2-5 May 2011. Cancer Immunol Immunother (2011) 0.75